1-Minute Consult

What screening approach could improve early detection of ‘at-risk’ metabolic dysfunction–associated steatohepatitis in my patients?

Zehra Naseem, MD, Yael Mauer, MD, MPH and Sobia Laique, MD
Cleveland Clinic Journal of Medicine July 2026, 93 (7) 397-401; DOI: https://doi.org/10.3949/ccjm.93a.26013

Article Information

vol. 93 no. 7 397-401
DOI 
https://doi.org/10.3949/ccjm.93a.26013
PubMed 
42386357
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online July 1, 2026.
Copyright & Usage 
Copyright © 2026 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Zehra Naseem, MD
  1. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  1. Yael Mauer, MD, MPH
  1. Co-Director, Multidisciplinary MASLD Clinic, Cleveland Clinic, Cleveland, OH; Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Sobia Laique, MD⇑
  1. Chair, MASLD Task Force, and Director, Multidisciplinary MASLD Clinic, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Address:
    Sobia Laique, MD, Department of Gastroenterology, Hepatology and Nutrition, A51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; laiques2{at}ccf.org
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects